David E Adson1, Michael Kotlyar. 1. Department of Psychiatry, School of Medicine, University of Minnesota, Minneapolis, MN, USA. adson001@umn.edu
Abstract
OBJECTIVE: To report a case of premature ejaculation occurring subsequent to citalopram discontinuation. CASE SUMMARY: A 43-year-old white man being treated for depression with citalopram wished to discontinue treatment. Four or 5 days after stopping citalopram he reported that, during sexual intercourse, his genitals seemed to be extremely sensitive and orgasm was achieved within approximately 1 minute. These symptoms continued over the next 3-4 weeks and remitted after citalopram was restarted. Several subsequent attempts to discontinue citalopram resulted in a return of these symptoms despite using a slow tapering regimen. An objective causality assessment revealed a probable relationship between drug withdrawal and the observed symptoms. DISCUSSION: The ability of selective serotonin-reuptake inhibitors (SSRIs) to delay ejaculation has been well documented; however, discontinuation of these agents generally results in a return to baseline function. Although discontinuation of SSRI therapy has been associated with a number of withdrawal symptoms, this is the first report (MEDLINE, September 2003), to our knowledge, of the emergence of sexual adverse effects in someone with no previous history of these symptoms. CONCLUSIONS: Premature ejaculation is a possible withdrawal effect after SSRI discontinuation. Since patients are usually reluctant to spontaneously report sexual adverse effects, it is important to specifically inquire about them both when starting and stopping treatment with an SSRI.
OBJECTIVE: To report a case of premature ejaculation occurring subsequent to citalopram discontinuation. CASE SUMMARY: A 43-year-old white man being treated for depression with citalopram wished to discontinue treatment. Four or 5 days after stopping citalopram he reported that, during sexual intercourse, his genitals seemed to be extremely sensitive and orgasm was achieved within approximately 1 minute. These symptoms continued over the next 3-4 weeks and remitted after citalopram was restarted. Several subsequent attempts to discontinue citalopram resulted in a return of these symptoms despite using a slow tapering regimen. An objective causality assessment revealed a probable relationship between drug withdrawal and the observed symptoms. DISCUSSION: The ability of selective serotonin-reuptake inhibitors (SSRIs) to delay ejaculation has been well documented; however, discontinuation of these agents generally results in a return to baseline function. Although discontinuation of SSRI therapy has been associated with a number of withdrawal symptoms, this is the first report (MEDLINE, September 2003), to our knowledge, of the emergence of sexual adverse effects in someone with no previous history of these symptoms. CONCLUSIONS: Premature ejaculation is a possible withdrawal effect after SSRI discontinuation. Since patients are usually reluctant to spontaneously report sexual adverse effects, it is important to specifically inquire about them both when starting and stopping treatment with an SSRI.
Authors: Ege Can Serefoglu; Chris G McMahon; Marcel D Waldinger; Stanley E Althof; Alan Shindel; Ganesh Adaikan; Edgardo F Becher; John Dean; Francois Giuliano; Wayne Jg Hellstrom; Annamaria Giraldi; Sidney Glina; Luca Incrocci; Emmanuele Jannini; Marita McCabe; Sharon Parish; David Rowland; R Taylor Segraves; Ira Sharlip; Luiz Otavio Torres Journal: Sex Med Date: 2014-06 Impact factor: 2.491
Authors: Stanley E Althof; Chris G McMahon; Marcel D Waldinger; Ege Can Serefoglu; Alan W Shindel; P Ganesan Adaikan; Edgardo Becher; John Dean; Francois Giuliano; Wayne Jg Hellstrom; Annamaria Giraldi; Sidney Glina; Luca Incrocci; Emmanuele Jannini; Marita McCabe; Sharon Parish; David Rowland; R Taylor Segraves; Ira Sharlip; Luiz Otavio Torres Journal: Sex Med Date: 2014-06 Impact factor: 2.491
Authors: David Healy; Audrey Bahrick; Maarten Bak; Angelo Barbato; Rocco Salvatore Calabrò; Barbara M Chubak; Fiammetta Cosci; Antonei B Csoka; Barbara D'Avanzo; Silvia Diviccaro; Silvia Giatti; Irwin Goldstein; Heiko Graf; Wayne J G Hellstrom; Michael S Irwig; Emmanuele A Jannini; Paddy K C Janssen; Mohit Khera; Manoj Therayil Kumar; Joanna Le Noury; Michał Lew-Starowicz; David E J Linden; Celine Lüning; Dee Mangin; Roberto Cosimo Melcangi; Omar Walid Muquebil Ali Al Shaban Rodríguez; Jalesh N Panicker; Arianna Patacchini; Amy M Pearlman; Caroline F Pukall; Sanjana Raj; Yacov Reisman; Rachel S Rubin; Rudy Schreiber; Stuart Shipko; Barbora Vašečková; Ahad Waraich Journal: Int J Risk Saf Med Date: 2022